Summary
3.03 0.13(4.49%)05/16/2024
Cronos Group Inc (CRON)
Cronos Group Inc (CRON)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.19 | -10.36 | -2.40 | 23.36 | 39.68 | 32.66 | -82.90 | 1,500.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.64 | |
| Open | 2.64 | |
| High | 2.68 | |
| Low | 2.60 | |
| Volume | 1,510,691 | |
| Change | -0.01 | |
| Change % | -0.19 | |
| Avg Volume (20 Days) | 3,641,725 | |
| Volume/Avg Volume (20 Days) Ratio | 0.41 | |
| 52 Week Range | 1.64 - 2.99 | |
| Price vs 52 Week High | -11.71% | |
| Price vs 52 Week Low | 60.98% | |
| Range | 0.00 | |
| Gap Up/Down | -0.15 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,140 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 6.03 | |
| Book Value | 4.3910 | |
| Earnings Per Share | -0.4060 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | -0.4700 | |
| EPS Estimate Next Year | -0.3000 | |
| Diluted EPS (TTM) | -0.4060 | |
| Revenues | ||
| Profit Marging | -2.5859 | |
| Operating Marging (TTM) | -3.4175 | |
| Return on asset (TTM) | -0.0645 | |
| Return on equity (TTM) | -0.0892 | |
| Revenue TTM | 56,637,000 | |
| Revenue per share TTM | 0.1570 | |
| Quarterly Revenue Growth (YOY) | 0.5810 | |
| Quarterly Earnings Growth (YOY) | -0.8860 | |
| Gross Profit (TTM) | -25,833,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.9701 | |
| Revenue Enterprise Value | 8.8341 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 371,806,016 | |
| Shares Float | 196,027,039 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 47.24 | |
| Institutions (%) | 16.28 | |
05/16 16:30 EST - investorplace.com
7 Penny Stocks to Buy for 100% Returns on Potential Policy Shifts
When policymakers pursue rate cuts, the main idea is to lower the cost of money for businesses and consumers. This translates into higher investment and consumption spending and GDP growth accelerates.
7 Penny Stocks to Buy for 100% Returns on Potential Policy Shifts
When policymakers pursue rate cuts, the main idea is to lower the cost of money for businesses and consumers. This translates into higher investment and consumption spending and GDP growth accelerates.
05/16 16:26 EST - investorplace.com
Cannabis Stocks CGC, TLRY, ACB, MSOS, CRON Pop as Justice Department Moves on Rescheduling
Cannabis stocks are once again on the move today, with some big names being seen across the sector. Shares of Canopy Growth (NASDAQ: CGC ), Tilray (NASDAQ: TLRY ), Aurora Cannabis (NASDAQ: ACB ), AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS ), and Cronos (NASDAQ: CRON ) are all up between 2% and 10% in today's session, with Canopy Growth leading the way higher.
Cannabis Stocks CGC, TLRY, ACB, MSOS, CRON Pop as Justice Department Moves on Rescheduling
Cannabis stocks are once again on the move today, with some big names being seen across the sector. Shares of Canopy Growth (NASDAQ: CGC ), Tilray (NASDAQ: TLRY ), Aurora Cannabis (NASDAQ: ACB ), AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS ), and Cronos (NASDAQ: CRON ) are all up between 2% and 10% in today's session, with Canopy Growth leading the way higher.
05/15 08:08 EST - marketwatch.com
Card payments remain a ‘challenge' for legal cannabis as major banks avoid the sector. Changing classification won't help.
When Ellis Soodak was planning the launch of Verdi Cannabis dispensary in New York City, he didn't want to face the dangers his father did at the family's liquor store in the 1970s and 80s.
Card payments remain a ‘challenge' for legal cannabis as major banks avoid the sector. Changing classification won't help.
When Ellis Soodak was planning the launch of Verdi Cannabis dispensary in New York City, he didn't want to face the dangers his father did at the family's liquor store in the 1970s and 80s.
05/11 09:17 EST - marijuanastocks.com
This Is How Marijuana Stocks Will Be Impacted By Reform In 2024
As the cannabis industry continues its growth in 2024, a confluence of regulatory, demographic, and market trends is shaping the sector. This has presented a fertile ground for savvy investors. Here's a deeper look into the evolving landscape of cannabis investments. This year could mark a significant turning point with the potential rescheduling of cannabis at the federal level. If cannabis can one day be federally legal it would be the biggest win for the industry.
This Is How Marijuana Stocks Will Be Impacted By Reform In 2024
As the cannabis industry continues its growth in 2024, a confluence of regulatory, demographic, and market trends is shaping the sector. This has presented a fertile ground for savvy investors. Here's a deeper look into the evolving landscape of cannabis investments. This year could mark a significant turning point with the potential rescheduling of cannabis at the federal level. If cannabis can one day be federally legal it would be the biggest win for the industry.
05/10 08:52 EST - investorplace.com
7 Massively Undervalued Penny Stocks to Buy for 7-Bagger Returns
My view is that expansionary monetary policy in the second half of 2024 is likely to be a major catalyst for a broad-based market rally. It's therefore a good time to accumulate high-quality growth stocks.
7 Massively Undervalued Penny Stocks to Buy for 7-Bagger Returns
My view is that expansionary monetary policy in the second half of 2024 is likely to be a major catalyst for a broad-based market rally. It's therefore a good time to accumulate high-quality growth stocks.
05/09 09:19 EST - investorplace.com
7 Cannabis Stocks to Buy for a Smoking-Hot 2024
Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.
7 Cannabis Stocks to Buy for a Smoking-Hot 2024
Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.
05/09 07:52 EST - marketwatch.com
Cronos' stock rallies after revenue rises to a record, amid strength in cannabis flower sales
Shares of Cronos Group Inc. CRON CA:CRON climbed 3.1% in premarket trading, after the cannabis company reported revenue that rose to a record and beat expectations, citing strength in flower sales in Canada and Israel. The company reported a net loss of $24.7 million, or 1 cent a share, after a loss of $16.8 million, or 5 cents a share, in the same period a year ago, to match the FactSet consensus for per-share losses of 1 cent.
Cronos' stock rallies after revenue rises to a record, amid strength in cannabis flower sales
Shares of Cronos Group Inc. CRON CA:CRON climbed 3.1% in premarket trading, after the cannabis company reported revenue that rose to a record and beat expectations, citing strength in flower sales in Canada and Israel. The company reported a net loss of $24.7 million, or 1 cent a share, after a loss of $16.8 million, or 5 cents a share, in the same period a year ago, to match the FactSet consensus for per-share losses of 1 cent.
05/09 07:30 EST - globenewswire.com
Cronos Group Reports 2024 First Quarter Results
Industry-leading balance sheet with $855 million in cash and cash equivalents Net revenue in Q1 2024 increased by 30% year-over-year to $25.3 million Spinach ® was top-3 in retail sales in Canada in the flower, edible, and vape categories in Q1 2024 Launched PEACE NATURALS ® brand in the United Kingdom in May 2024 TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2024 first quarter business results. “Cronos achieved its highest quarterly net revenue from continuing operations on record at $25.3 million, up 30% year-over-year.
Cronos Group Reports 2024 First Quarter Results
Industry-leading balance sheet with $855 million in cash and cash equivalents Net revenue in Q1 2024 increased by 30% year-over-year to $25.3 million Spinach ® was top-3 in retail sales in Canada in the flower, edible, and vape categories in Q1 2024 Launched PEACE NATURALS ® brand in the United Kingdom in May 2024 TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2024 first quarter business results. “Cronos achieved its highest quarterly net revenue from continuing operations on record at $25.3 million, up 30% year-over-year.
05/07 14:00 EST - investorplace.com
The 3 Best Meme Stocks to Buy in May 2024
The rules of investing have significantly changed over the years. That particularly holds true for investors looking for short-term gains.
The 3 Best Meme Stocks to Buy in May 2024
The rules of investing have significantly changed over the years. That particularly holds true for investors looking for short-term gains.
05/07 07:00 EST - globenewswire.com
Cronos Enters United Kingdom Cannabis Market
TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it is expanding its medical brand, PEACE NATURALS, into the United Kingdom market with its first shipment of cannabis flower to GROW® Pharma, a leading distributor of prescribed medicinal cannabis products in the UK.
Cronos Enters United Kingdom Cannabis Market
TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it is expanding its medical brand, PEACE NATURALS, into the United Kingdom market with its first shipment of cannabis flower to GROW® Pharma, a leading distributor of prescribed medicinal cannabis products in the UK.
05/03 23:43 EST - seekingalpha.com
Cannabis Continues Powering To Big Gains With Historic DEA Rescheduling
The proposed rescheduling of cannabis is the biggest step forward for the industry in decades.
Cannabis Continues Powering To Big Gains With Historic DEA Rescheduling
The proposed rescheduling of cannabis is the biggest step forward for the industry in decades.
05/02 14:00 EST - marijuanastocks.com
May 2024 Watchlist: Leading Canadian Cannabis Stocks Poised for Growth
As May 2024 begins, Canadian cannabis companies are catching the eye of savvy investors. Among these, Canopy Growth Corporation and Aurora Cannabis stand out for their expansive market reach and innovation. These companies have been pioneers in the cannabis industry, expanding their operations globally. They are well-positioned to capitalize on emerging markets. This is due to their early entry and continuous investment in research and development.
May 2024 Watchlist: Leading Canadian Cannabis Stocks Poised for Growth
As May 2024 begins, Canadian cannabis companies are catching the eye of savvy investors. Among these, Canopy Growth Corporation and Aurora Cannabis stand out for their expansive market reach and innovation. These companies have been pioneers in the cannabis industry, expanding their operations globally. They are well-positioned to capitalize on emerging markets. This is due to their early entry and continuous investment in research and development.
05/01 15:13 EST - fool.com
Why Canopy Growth, Tilray, and Cronos Group Stocks Just Cratered
The DEA recommended loosening regulations on marijuana yesterday. As a Schedule III drug, marijuana would still be regulated and some costs would rise for cannabis companies -- but others would fall.
Why Canopy Growth, Tilray, and Cronos Group Stocks Just Cratered
The DEA recommended loosening regulations on marijuana yesterday. As a Schedule III drug, marijuana would still be regulated and some costs would rise for cannabis companies -- but others would fall.
05/01 06:37 EST - investorplace.com
Stock Market Crash Alert: 3 Must-Buy Cannabis Stocks When Prices Plunge
Warren Buffett is a well-known proponent of value investing. The legendary investor waits for the right valuation before making a big plunge.
Stock Market Crash Alert: 3 Must-Buy Cannabis Stocks When Prices Plunge
Warren Buffett is a well-known proponent of value investing. The legendary investor waits for the right valuation before making a big plunge.
04/30 20:49 EST - marketwatch.com
U.S. poised to ease restrictions on marijuana in historic shift, though it'll remain controlled substance
WASHINGTON — The U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, the Associated Press has learned, a historic shift to generations of American drug policy that could have wide ripple effects across the country.
U.S. poised to ease restrictions on marijuana in historic shift, though it'll remain controlled substance
WASHINGTON — The U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, the Associated Press has learned, a historic shift to generations of American drug policy that could have wide ripple effects across the country.
04/30 17:41 EST - news.sky.com
US plans to reclassify cannabis as less dangerous drug
The US is planning to reclassify cannabis as a less dangerous drug in an historic shift that could have a significant impact across the country.
US plans to reclassify cannabis as less dangerous drug
The US is planning to reclassify cannabis as a less dangerous drug in an historic shift that could have a significant impact across the country.
04/30 17:38 EST - youtube.com
Pot Stocks Rally as DEA Moves to Reclassify Marijuana as Less Dangerous Drug
Pot stocks rally as the DEA moves to reclassify marijuana as a less dangerous drug. Renita Young discusses this as the DEA's proposal needs to be reviewed by the White House Office of Management and Budget.
Pot Stocks Rally as DEA Moves to Reclassify Marijuana as Less Dangerous Drug
Pot stocks rally as the DEA moves to reclassify marijuana as a less dangerous drug. Renita Young discusses this as the DEA's proposal needs to be reviewed by the White House Office of Management and Budget.
04/30 16:15 EST - fool.com
Why Cannabis Companies Tilray, Canopy Growth, Cronos, and SNDL Got Really High on Tuesday
The DEA officially agreed to recommend rescheduling cannabis from a Class I to a Class III drug. While it doesn't legalize cannabis, the measure has the potential to be hugely impactful to U.S. multi-state operators.
Why Cannabis Companies Tilray, Canopy Growth, Cronos, and SNDL Got Really High on Tuesday
The DEA officially agreed to recommend rescheduling cannabis from a Class I to a Class III drug. While it doesn't legalize cannabis, the measure has the potential to be hugely impactful to U.S. multi-state operators.
04/30 15:12 EST - reuters.com
Pot stocks jump as U.S. DOJ moves to reclassify cannabis as a less dangerous drug
Shares of cannabis companies surged on Tuesday afternoon after the U.S. Department of Justice (DoJ) moved to reclassify marijuana as a less dangerous drug.
Pot stocks jump as U.S. DOJ moves to reclassify cannabis as a less dangerous drug
Shares of cannabis companies surged on Tuesday afternoon after the U.S. Department of Justice (DoJ) moved to reclassify marijuana as a less dangerous drug.
04/30 14:39 EST - proactiveinvestors.com
Cannabis stocks surge on reports DEA will approve rescheduling of marijuana as lower-risk drug
Cannabis stocks surged on Tuesday afternoon following multiple media reports that the US Drug Enforcement Administration will approve the reclassification of marijuana as a lower-risk drug. The news was first reported by the Associated Press, which cited five people familiar with the matter.
Cannabis stocks surge on reports DEA will approve rescheduling of marijuana as lower-risk drug
Cannabis stocks surged on Tuesday afternoon following multiple media reports that the US Drug Enforcement Administration will approve the reclassification of marijuana as a lower-risk drug. The news was first reported by the Associated Press, which cited five people familiar with the matter.